An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and Stromal Vascular Fraction
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- efficacy (measured as an absence of purulent collections superior to 2 cms concerning the fistula measured clinically and by MRI)
研究概览
简要总结
Crohn's disease is a chronic inflammation of all or part of the digestive tract, " from the mouth to the anus ". .
Cell therapy is a new and promising approach for the treatment of inflammatory disease including Crohn's disease and fistulas.
Adipose tissue seems to be an ideal source for cell therapy. This is a prospective, open, non-comparative, single center, phase I-II clinical trial. It will involve 10 patients and will be conducted over a period of 28 month.
This protocol is designed to evaluate, in patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, the safety and efficacy of local microinjection of autologous adipose tissue and SVF from microaspirate .
The main objective is to assess tolerance and security. The secondary objective is to evaluate the effectiveness of this technique
详细描述
Crohn's disease is a chronic inflammation of all or part of the digestive tract, " from the mouth to the anus ". Anoperineal lesions are a very frequent entity in this disease (20 to 80%) and a real therapeutic challenge. Among these lesions, we were interested in fistula-in-ano that are currently difficult to treat despite a large therapeutic arsenal.
Cell therapy is a new and promising approach for the treatment of inflammatory disease including Crohn's disease and fistulas.
Indeed, stem cells have shown some efficacy in several indications through their differentiation potential, including fistula-in-ano in Crohn's disease.
Adipose tissue seems to be an ideal source for cell therapy This is a prospective, open, non-comparative, single center, phase I-II clinical trial. It will involve 10 patients and will be conducted over a period of 28 month.
This protocol is designed to evaluate, in patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, the safety and efficacy of local microinjection of autologous adipose tissue and SVF from microaspirate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease of Crohn diagnosed for at least 6 months according to the recognized clinical, endoscopic and histological criteria
- •Presence of fistulas died anal complex estimated by clinical examination and MRI. A fistula died anal complex is, by definition, a fistula which answers at least one of the following criteria during its evolution: (1) high, trans-sphincter, extra-sphincter or above sphincter Inter-sphincter. (2) Presence of = 2 external openings. (3) Purulent Collections associated
- •Active or slightly active Crohn luminal, defined by a CDAI (Crohn's Disease Activity Index) = 220
排除标准
- •Disease of Crohn activates mainly luminal with a CDAI = 220 requiring an immediate treatment
- •Patients having never received specific treatments of the anal died disease of Crohn with fistula, including by antibiotics
- •Presence of an abscess or collections of more than 2 cms unless this problem is solved during the period of preparation
- •Rectal and/or anal Stenosis and/or active proctitis, if it means a limitation of the surgical procedure
- •Patient having undergone an operation of the fistula other than the drainage
- •Patients under corticoids or by having receiving in the previous four weeks
- •Active Malignant Tumors or history of Malignant tumors
研究组 & 干预措施
Crohn's disease treated by SVF
Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
干预措施: stromal vascular fraction (SVF) (Drug)
结局指标
主要结局
efficacy (measured as an absence of purulent collections superior to 2 cms concerning the fistula measured clinically and by MRI)
时间窗: 48 weeks
the patient is monitored with regular consultations at weeks 1, 2, 8, 16 et 48 and paraclinical (blood sample (hemogram , coagulation factors) and magnetic resonance imaging of the perineum) at weeks 8 and 48 to evaluate effectiveness of treatment. The efficacy of treatment is measured as an absence of purulent collections superior to 2 cms concerning the fistula treated at 12 and 48 weeks measured clinically and by MRI
safety (measured by an absence of fever and local inflammatories symptoms)
时间窗: 48 weeks
the patient is monitored with regular consultations at weeks 1, 2, 8, 16 et 48 and paraclinical (blood sample (hemogram and coagulation factors) and magnetic resonance imaging of the perineum) at weeks 8 and 48 to evaluate tolerance of treatment. The safety is measured by an absence of fever and local inflammatories symptoms measured at week 1, 2,8, 16 and 48
次要结局
- improvement of quality of life (assessed by questionnaire)(48 weeks)